Sunday July 23rd 2017

Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

Antisense Therapeutics Limited is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Phase II trial of ATL1103 for the growth disorder, acromegaly. This satisfies the necessary patient numbers proposed for the trial.

Visit site: 

Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

Leave a Comment

More from category

Mothers who breastfeed might have lower multiple sclerosis risk
Mothers who breastfeed might have lower multiple sclerosis risk

(Reuters Health) - Women who breastfeed may have a lower risk of developing multiple sclerosis later in life compared [Read More]

Lipoic acid in nutritional supplements found to help prevent multiple sclerosis, study finds
Lipoic acid in nutritional supplements found to help prevent multiple sclerosis, study finds

(Natural News) The results of a new pilot study showed the efficacy of lipoic acid in the reduction of whole brain [Read More]

Multiple sclerosis symptoms: Immune system problems can trigger PARALYSIS of the legs
Multiple sclerosis symptoms: Immune system problems can trigger PARALYSIS of the legs

MULTIPLE sclerosis - commonly abbreviated to MS - is a type of autoimmune disease which can cause problems with vision, [Read More]

National Patient-Advocacy Organizations Oppose ACA Repeal
National Patient-Advocacy Organizations Oppose ACA Repeal

/About-the-Society/News/National-Patient-Advocacy-Organizations-Oppose-ACA [Read More]

Exclusive: Nurses reluctant to discuss disability with MS patients
Exclusive: Nurses reluctant to discuss disability with MS patients

Nearly two-thirds of specialist nurses are reluctant to discuss disability with patients who have multiple sclerosis, [Read More]